Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral contraceptives. Risks.

L P Shulman1

  • 1Department of Obstetrics and Gynecology, University of Illinois at Chicago, USA. lps5@cornell.edu

Obstetrics and Gynecology Clinics of North America
|November 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESC expert statement on the effects on mood of the natural cycle and progestin-only contraceptives.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2017
Same author

Contraception for the perimenopausal woman.

Climacteric : the journal of the International Menopause Society·2016
Same author

Pharmacokinetics of 23-epi-26-deoxyactein in women after oral administration of a standardized extract of black cohosh.

Clinical pharmacology and therapeutics·2009
Same author

Androgens and menopause.

Minerva ginecologica·2009
Same author

Alternatives to oral regimens of contraception.

Minerva ginecologica·2007
Same author

[Late first-trimester invasive prenatal diagnosis--secondary publication. An international randomized trial].

Ugeskrift for laeger·2005
Same journal

Bridging Science and Practice in Gender-Affirming Care: A Compendium for Gynecologists.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evidence, Clinical Expertise, and Research Gaps in Gender-Affirming Care.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evaluation and Management of the Pediatric Gender-Diverse Patient.

Obstetrics and gynecology clinics of North America·2026
Same journal

Expanding Access to Cervical Cancer Screening for Transgender and Nonbinary Individuals.

Obstetrics and gynecology clinics of North America·2026
Same journal

Updates on Breast Cancer Screening and Special Considerations for Transgender Men and Women.

Obstetrics and gynecology clinics of North America·2026
Same journal

Contraceptive Needs of the Transmasculine Patient.

Obstetrics and gynecology clinics of North America·2026
See all related articles

Modern combination oral contraceptives (OCs) are safe and effective for women. Despite unfounded fears about risks like breast cancer, OCs offer significant noncontraceptive benefits, promoting informed choices and preventing unintended pregnancies.

Area of Science:

  • Reproductive Health
  • Pharmacology
  • Public Health

Background:

  • Combination oral contraceptives (OCs) are widely used for reliable contraception.
  • Past safety concerns regarding OC use have been extensively studied and largely resolved.
  • Misperceptions persist regarding OC risks and benefits, potentially limiting use.

Purpose of the Study:

  • To review the safety profile of modern combination oral contraceptives.
  • To highlight the noncontraceptive benefits of oral contraceptives.
  • To address persistent misperceptions about oral contraceptive risks, including breast cancer.

Main Methods:

  • Comprehensive review of existing scientific literature and safety studies on oral contraceptives.
  • Analysis of data regarding the risks and noncontraceptive benefits of OCs.

Related Experiment Videos

  • Evaluation of evidence addressing concerns about oral contraceptives and breast cancer risk.

    • Main Results:

    • Extensive research confirms the safety of modern, low-dose combination oral contraceptives.
    • Numerous noncontraceptive benefits associated with OC use are often overlooked.
    • Data does not substantiate fears linking oral contraceptive use to increased breast cancer risk.

    Conclusions:

    • Clinicians should recognize the established safety of low-dose OCs.
    • Accurate counseling on OC safety and benefits is crucial for informed decision-making.
    • Addressing misperceptions can improve OC utilization and reduce unintended pregnancies.